Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Indices

For the sixth consecutive year, Roche has been recognized by the Dow Jones Sustainability Indices (DJSI) as the Group Leader in sustainability within the pharmaceuticals, biotechnology, and life sciences industry. This places Roche amongst the top 10 percent of companies across all surveyed industries. Inclusion in the DJSI is based on an in-depth analysis of economic, social, and environmental performance, assessing issues such as corporate governance, stakeholder engagement, risk management, supply chain standards, and labor practices.

In this year’s DJSI assessment, Roche received the highest scores in the industry in several areas. These include how Roche manages customer relationships, supply chain management, and how Roche helps address healthcare burden through the value of its products and services. Roche also scored the highest marks in nearly every area of employee engagement, including developing employees, respecting human rights, and attracting and retaining good talent.

“It is very rewarding for us that Roche continues to be recognized as the most sustainable company within our peer group,” says Severin Schwan, CEO of Roche. We remain committed to lasting innovation as our greatest contribution to society and a sustainable future for us all.”

In 2009 Roche introduced a number of five-year Corporate Goals along with Key Performance Indicators to measure progress. Among these, Roche introduced a diversity objective to increase the percentage of women in key positions by at least 50 percent, as well as an energy-efficiency goal of reducing energy consumption and increasing energy efficiency by 10 percent by the end of 2014. Roche reached the diversity goal by the end of 2013, one year ahead of schedule, and the energy target at the end of 2012, two years early. In addition, as access to healthcare is an issue in many parts of the world, Roche is actively working with governments, healthcare professionals, NGOs, and other organizations globally to improve access to its medicines and diagnostics. Learn more about the DJSI.